Physicians' Academy for Cardiovascular Education

DPP-4 inhibitor reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

June 15, 2016 - news

DPP-4 inhibitor linagliptin (5 mg, once daily) is used along with diet and exercise to improve glycaemic control in adults with type 2 diabetes (T2DM). Results from the MARLINA-T2D trial demonstrated that linagliptin reduced blood sugar in adults with T2DM who are at risk for kidney impairment with a renal safety profile similar to that seen in other trials. 

“Up to half of people with T2DM experience long-term problems with kidney function,” said Professor Per-Henrik Groop, Professor of Nephrology, and Chief Physician at the Division of Nephrology, Helsinki University Central Hospital, Helsinki, Finland and Principal Investigator of the MARLINA-T2D trial. “Diabetes treatment options are generally limited for this group. These results support the use of linagliptin, with just one dose for all patients, including those with T2DM who have early signs of kidney disease.”

In people who have diabetes, high levels of blood glucose can damage the kidneys' filters. Over time, the damage can increase the risk for developing kidney impairment. One of the first signs of damaged kidneys and early stage kidney disease is albuminuria that indicates risk for further worsening of kidney function.

MARLINA-T2D examined the safety and efficacy of linagliptin versus placebo in 360 patients with T2D and albuminuria (defined as urinary albumin-to-creatinine ratio (UACR) 30-3000 mg/g creatinine). At 24 weeks, linagliptin was associated with a significant 0.6 percent reduction in A1C (a measure of average blood glucose over the past two to three months) versus placebo. Change in albuminuria, as measured by UACR, was non-significant with linagliptin versus placebo. Linagliptin was well tolerated in the trial, with a renal safety profile consistent with that of previous clinical trials. According to the MARLINA-T2D trial, linagliptin does not require dose adjustment based on renal function.
Press release Boehringer Ingelheim June 11, 2016